Navigation Links
Ventas Completes Previously Announced Sale of Common Stock
Date:2/1/2008

Company Receives Net Proceeds of $191.9 Million

LOUISVILLE, Ky., Feb. 1 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") announced today that it has completed the sale of 4,485,000 shares of its common stock pursuant to the Company's existing shelf registration statement. The amount includes 585,000 shares of common stock that were sold pursuant to the exercise of the underwriter's overallotment option. The Company received net proceeds, before expenses, of $191.9 million, which the Company will use to repay indebtedness outstanding under its revolving credit facility and for working capital and other general corporate purposes, including to fund future acquisitions. As previously announced, the shares were sold to UBS Investment Bank, as sole underwriter, at a price of $42.78 per share.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Ventas, Inc.'s ("Ventas" or the "Company") and its subsidiaries' expected future financial position, results of operations, cash flows, funds from operations, dividends and dividend plans, financing plans, business strategy, budgets, projected costs, capital expenditures, competitive positions, acquisitions, investment
'/>"/>

SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
2. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
3. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
4. Ventas Appoints Brush SVP - Senior Housing Development and Operations
5. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
6. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
7. Ventas Enters Agreement to Sell Common Stock
8. Eligard(R) six-month formulation successfully completes European approval procedure
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ved effective against Lennox-Gastaut syndrome , ...w drug called Banzel (rufinamide) has been approve...f epilepsy called Lennox-Gastaut syndrome, the U.S..., The approval was based on results of a four-mo...o 30. Compared to patients who took a placebo, tho...
(Date:11/21/2008)...21 New research at Wes...eless, spitless tobacco product aimed at young adu... that RJ Reynolds, Camel Snus - touted as a social...surprisingly high levels of nicotine. , , "...snuff products," said Bruce Adkins of the state Di...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3
...earchers from the Johns Hopkins Department of had ...y in the heart after a heart attack. // The resea...called SPECT/CT, to successfully trace stem cells’... injected into the body to treat animal hearts dam...
...ple suffering from anorexia nervosa have the simil...d other emotional disorders. // The study was publ...l Psychiatry. Previous evidence has suggested that...nin (a brain chemical involved in communication be...
...ral tube defects are congenital deformities that a...ifida and anencephaly are the two most common form...s paralysis in spina bifida and fatal brain deform...t can be diagnosed by antenatal ultrasound, nothin...
... aortic valve in the heart is the valve that gover...ely the aorta, which supplies blood to various org...wing back inside the heart from the rest of the bo...heart depends on the proper functioning of the aor...
Other Medicine News:Health News:Percutaneous aortic valve replacement- a revolution in Cardiac Surgery 2
(Date:11/20/2008)...LE, Calif., Nov. 20 Bion... will present results from the Phase 1B,clinical ...tastatic breast,cancer, BZL101, at the Society fo...erence in Atlanta, Georgia. The Company,s oral pr... and will be presented as a part of the Best of th...
(Date:11/20/2008)...SO, Norway, November 20 The Scandi...arma has announced results of studies on its,lead...AC in Washington, DC,the studies showed that the...cteriocidal effect, significantly better towards k...ogenes than marketed gold standard drugs. In,addi...
(Date:11/19/2008)...ELLE, N.Y., Nov. 19 Biotech scient...es to toxicology research to better understand the...organ systems, reports Genetic Engineering & ...nterested in figuring out a new compound,s mechani...e toxicology technique, according to the November ...
(Date:11/18/2008)... Pa., Nov. 18 Arlington Medical Re...ligence for the pharmaceutical and diagnostic,ima...L Behring,s Privigen was,sold in the U.S. during ...,brand of intravenous immune globulin (IVIG) and w... a product created from the blood plasma of thousa...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 1Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 2Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 3Quality Lags at Safety Net Hospitals 19232 1Quality Lags at Safety Net Hospitals 19232 2Quality Lags at Safety Net Hospitals 19232 3
..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...elanoma vaccine clinical trial and data from the P... vaccine clinical trial will be,presented at the 2...3rd annual meeting in Chicago on June 1-5 2007. , ...cal and immunological responses in patients with m...
...e Patients Receiving Combination of,Bavituximab Pl...sponse or Stable Disease - , - 75% of Patients ...ine , ,Achieved Objective Tumor Response...Receiving Combination of Bavituximab Plus , ... Response - , - Trial Results Support Advanc...
Other Medicine Technology:IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 2IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 3IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 4IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 5IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 6Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003.
Athouritative, on the spot answers for acute care and consultations.
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
Medicine Products: